Introduction {#sec1-1}
============

*Acinetobacter* is a common isolate, especially in the hospital setting. Of late, the isolation of this pathogen has become a grave problem in the Intensive Care Units (ICUs). In fact, it is the second most common nonfermenting Gram-negative bacilli (NFGNB), causing bacterial infections after *Pseudomonas*. *Acinetobacter* is grouped under NFGNB. Its ability to acquire drug resistance has become a difficult problem, and recovery of pan-resistant *Acinetobacter* is not uncommon. *Acinetobacter* is oxidase negative, nonmotile, nonfermenting, Gram-negative, *coccobacillus*. Brison and Prevot (1954) proposed the generic designation, *Acinetobacter*. In 1971, the Subcommittee on Taxonomy of Moraxella and allied bacteria suggested that the genus *Acinetobacter* shall include only oxidase negative, nonmotile, nonfermenting, Gram-negative coccobacillus.\[[@ref1][@ref2]\]

At present, 33 genomospecies of *Acinetobacter* have been recognized by DNA--DNA hybridization. Among these species, *Acinetobacter calcoaceticus*, *Acinetobacter baumannii*, *Acinetobacter* genomic species 3, and *Acinetobacter* genomic species 13TU are very closely related and are difficult to distinguish from each other phenotypically. They are said to be saccharolytic strains. Therefore, they have been grouped as *A. calcoaceticus*-*A. baumannii* complex. This group accounts for 80% of the clinical infections caused by *Acinetobacter* spp. *A. baumannii* is the most frequently isolated species from human clinical specimens, followed by *Acinetobacter* spp. 3. *Androstachys johnsonii*, *Acinetobacter lwoffii*, and *Acinetobacter* spp. 12, which are nonsaccharolytic occur as natural inhabitants of human skin.\[[@ref2]\]

Molecular methods such as amplified 16S rRNA gene restriction analysis, high-resolution fingerprint analysis by amplified fragment length polymorphism, ribotyping, tRNA spacer fingerprinting, restriction analysis of the 16S--23S rRNA intergenic spacer sequences, and sequence analysis of the 16S--23S rRNA gene spacer region are in use for the identification of *Acinetobacter*. These methods are used in only a few reference laboratories and are not suitable for use in routine laboratories. Gundi *et al*. have shown that partial rpo B gene sequence analysis is a simple molecular tool for the identification and speciation of *Acinetobacter* clinical strains.\[[@ref2][@ref3]\]

We discuss here the development of in-house polymerase chain reaction (PCR) and its sensitivity and specificity for genus level identification of *Acinetobacter*. We also compared the accuracy of identification of genus *Acinetobacter* based on preliminary tests with phenotypic and molecular identification.

Methodology {#sec1-2}
===========

The study was conducted in the Department of Microbiology of a tertiary care center in North Karnataka. A total of 96 *Acinetobacter* isolates from various clinical samples such as endotracheal (ET) secretions, ET tubes, sputum, pus, blood, and cerebrospinal fluid and environmental isolates from surveillance cultures of the medical ICU were also included in this work. All the samples were processed according to the standard laboratory techniques. Three identification protocols, viz., identification based on preliminary biochemical tests, identification using standard biochemical and physiological tests, and PCR were used for the identification of the isolates.

The preliminary identification tests after the plate reading were Gram\'s stain, catalase test, oxidase test, and motility. Further identification was continued by standard biochemical and physiological tests.\[[@ref4][@ref5][@ref6][@ref7]\] All the isolates were also subjected to PCR, targeting 350 bp hypervariable region of *rpo*B gene.

Polymerase chain reaction {#sec2-1}
-------------------------

We used ATCC *A. baumannii* 19606 as reference strain for standardization of the in-house PCR. The strain was subcultured on brain--heart infusion (BHI) agar plate to check for purity. It was phenotypically reconfirmed. Two well-characterized colonies from BHI agar were inoculated into 1 ml of LuriaBertani (LB) broth and incubated overnight at 37°C. Extraction of DNA was carried out by phenol--chloroform method. The amplification was carried out using primers (Ac696FAc1093R) procured from Sigma-Aldrich, targeting 350 bp hypervariable zone in the rpo B gene specific to *Acinetobacter* species.\[[@ref3]\] The PCR mixture (50 μl) contained 2 μl DNA, PCR Master--Mix (2X) (Chromous Biotech), and primers at 0.2 μM concentration. The protocol for amplification used was initial denaturation at 94°C for 2 min, followed by 35 cycles of denaturation at 94°C for 30 s, annealing at 53°C for 30 s and extension at 72°C for 1 min followed by final elongation at 72°C for 7 min. The PCR product was resolved on 1% agarose gel containing ethidium bromide in Tris-acetate ethylenediaminetetraacetic acid buffer at 100 V for 1 h. The amplicon was examined and documented using gel doc system (Zenith Research, Mumbai).

The sensitivity and specificity of the in-house PCR were determined by harvesting growth from LB broths. LB broths were inoculated and incubated at 37°C for 24 h, and pellet was obtained by centrifugation at 3000 rpm for 5 min. The pellet was washed and resuspended in sterile nuclease free distilled water to obtain doubling dilutions from 1:2 to 1:128. DNA was extracted from these diluted samples by phenol--chloroform extraction method and subjected to PCR. The DNA concentration of the all the dilutions was estimated using Epoch™, Biotek spectrophotometer.

For determining the specificity, we subjected various routine bacterial isolates recovered in our bacteriology laboratory to this PCR. We tested *Staphylococcus aureus* (*n* = 4), *Enterococcus* spp. (*n* = 4), *Streptococcus* spp. (*n* = 4), *Moraxella* spp. (*n* = 4), *Klebsiella pneumoniae* (*n* = 4), *Escherichia coli* (*n* = 4), *Pseudomonas aeruginosa* (*n* = 4), *Salmonella Enterica* Typhi (*n* = 4), *Providencia rettgeri* (*n* = 4) NFGNB including *Stenotrophomonas* (*n* = 6). We used ATCC *A. baumannii* 19606 and well-characterized stock strains of *A. lwoffii* and *A. calcoaceticus* from our laboratory as positive controls. The PCR amplified all *Acinetobacter* whereas it did not amplify any of the non-*Acinetobacter* isolates.

A total of 96 *Acinetobacter* clinical isolates were subjected to the standardized PCR. One amplicon from a positive PCR reaction was randomly selected and sent for sequencing (Chromous Biotech, Bangalore) and analyzed by basic local alignment search tool which confirmed it to be belonging to the genus *Acinetobacter*.

Results {#sec1-3}
=======

Of the 96 *Acinetobacter* spp. included in the study, 87 were identified as *A. baumannii*, 5 as *A. calcoaceticus*, and 4 as *A. lwoffii* by standard biochemical and physiological tests. All the isolates were identified as *Acinetobacter* spp. by the preliminary tests, viz., Gram stain, catalase test, oxidase test, and motility by hanging drop preparation. All the 96 isolates successfully amplified the requisite target gene \[[Table 1](#T1){ref-type="table"}\].

###### 

Comparison of polymerase chain reaction and phenotypic identification protocols (*n*=96)

![](JLP-9-279-g001)

A set of 42 non-*Acinetobacter* isolates \[[Table 2](#T2){ref-type="table"}\] recovered from various samples were also subjected to the same PCR assay. All these 42 isolates did not show amplification for the target gene. Thus, there was 100% agreement between the preliminary phenotypic identification and PCR for genus level identification of *Acinetobacter* \[[Table 1](#T1){ref-type="table"}\].

###### 

Phenotypic and molecular identification

![](JLP-9-279-g002)

The overnight incubated LB broth of ATCC *A. baumannii* 19606 was diluted by doubling dilutions in distilled water and was subjected to PCR. The highest dilution that gave a positive amplification was 1:64. The DNA extracted from this dilution on quantitation by Epoch™, Biotek Spectrophotometer showed a concentration of 8.426 ng/μl.

Discussion {#sec1-4}
==========

*Acinetobacter* is the second most common NFGNB isolated in the clinical laboratories. *Acinetobacter* infection has emerged as a serious threat to the health-care system because of its multidrug resistance drifting to pan-resistance. Various mechanisms such as β-lactamase production, alterations in cell wall channels (porins), efflux pumps, and carbapenemase production have been recognized conferring resistance to this pathogen. Strains producing metallo-β-lactamase are frequently encountered. Therapy for carbapenem-resistant *Acinetobacter* is a serious problem. The current available choices such as polymyxins or tigecycline are also under threat of drug resistance.\[[@ref8][@ref9]\]

*Acinetobacter* is frequent colonizer of the hospital personnel, patients, and environment. Hands of the health-care workers, respiratory tract and skin of the patients, inanimate objects such as floor, bed, and computer keyboards are often colonized.\[[@ref8]\] Accurate identification and speciation of this organism are important for successful treatment as well as for epidemiological studies.

Many clinical laboratories stop at genus level identification of the *Acinetobacter* and do not go ahead with further biochemical analysis. The identification is mostly based on preliminary tests such as Gram\'s stain, catalase test, oxidase test, and hanging drop preparation for motility. An important test such as nitrate reduction test is also not used. As per the standard norms, the identification of any pathogen based on preliminary tests is not very reliable. Other NFGNBs such as *Burkholderia* spp. and *Stenotrophomonas* spp. are isolated frequently in clinical laboratories and the phenotypic identification of these organisms is uncertain. Identification of NFGNBs, giving the oxidase test negative, is an enigma for clinical laboratories. We, therefore, used an in-house PCR targeting a 350 bp rpo B gene for genus level identification of *Acinetobacter*. This PCR has been shown to be specific for identification of *Acinetobacter*.\[[@ref3]\] A total of 98 clinical isolates (including stock strains as internal control) and ATCC *Acinetobacter* 19606 strains of *Acinetobacter* \[[Table 2](#T2){ref-type="table"}\] were subjected to the in-house PCR. The clinical isolates were speciated by phenotypic tests. Of the 96 clinical isolates, 87 were *A. baumannii*, 5 were *A. calcoaceticus*, and 4 were *A. lwoffii*. All the phenotypically identified *Acinetobacter* gave amplification for the requisite target. Thus, there was 100% agreement between phenotypic identification and molecular identification of *Acinetobacter*. When 42 non-*Acinetobacter* bacterial isolates were subjected to this PCR, none of the isolates gave amplification for the target gene. This showed that the in-house PCR was highly specific for the genus *Acinetobacter*.

We tried to correlate the identification of *Acinetobacter* by preliminary tests (Gram stain, catalase, oxidase, and motility) and in-house PCR. It was observed that there was complete agreement between the preliminary identification and PCR \[[Table 1](#T1){ref-type="table"}\]. This is highly assuring for the clinical laboratories practicing identification of *Acinetobacter* based on preliminary tests. This shows that the preliminary tests commonly used by clinical laboratories for identification of *Acinetobacter* are reliable. Considering the importance of *Acinetobacter* in human infections, rapid identification of this organism is of paramount importance in treatment initiation and further management of the patients. A lot of clinical laboratories including tertiary care hospitals are still not using PCR routinely for logistic and financial constraints. This study indicates that the basic preliminary test protocols when implemented meticulously identify genus *Acinetobacter* precisely. This PCR assay needs to be further standardized for detection of *Acinetobacter* with its drug resistance profile directly from clinical specimens, which will be a boon to hasten the patient care. This assay also may also have a prominent role in the infection control practices.

The three most clinically relevant *Acinetobacter* species are *A. baumannii*, *Acinetobacter nosocomialis* (formerly *Acinetobacter* genomic species 13TU), and *Acinetobacter pittii* (formerly *Acinetobacter* genomic species 3).\[[@ref10]\] However, these cannot be differentiated by phenotypic tests including the automated identification systems such as API 20NE, Vitek2, Phoenix, and MicroScan WalkAway systems. Molecular methods such as the detection of *bla*OXA51like, the intrinsic carbapenemase gene in *A. baumannii*, and sequencing of the *rpo*B gene have helped to identify and speciate the genus. *A. baumannii* is the most resistance one of the genomospecies and has substantial clinical relevance. This pathogen is the most frequently isolated species and is typically associated with outbreaks in the hospital setting.\[[@ref2]\] It is endowed with resistance to harsh environmental factors, enabling it to establish and spread rapidly in the hospital environment.\[[@ref11][@ref12][@ref13]\]

Considering the increasing threat of this highly drug-resistant pathogen as a hospital as well as community pathogen, it is very important to identify it quickly and accurately as *Acinetobacter*. Rapid identification will be important for therapeutic as well as epidemiological needs to identify and check the spread of this pathogen. Immediate implementation of disinfection methods and alarming the hospital personnel about the presence of this pathogen will help mitigate the menace.

Conclusion {#sec1-5}
==========

The phenotypic identification based on preliminary tests commonly practiced in clinical laboratories has excellent correlation with the molecular identification. Accurate identification of genus *Acinetobacter* can be performed using preliminary tests, viz., Gram stain, catalase, oxidase, and motility, which can be easily performed in any clinical laboratory. In-house PCR standardized in our study is specific and sensitive for the identification of *Acinetobacter* species. There is a need to standardize this PCR assay for direct identification of *Acinetobacter* from the clinical specimens.
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